Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

While disappointing, the failure of these trials was more likely than not, and we are not changing our fair value estimate.

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

Eli Lilly LLY secured a significant milestone on Friday when it became the first company in the healthcare space to reach $1 ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...